DLP
NEPH icon

De Lisle Partners’s Nephros NEPH Stock Holding History

De Lisle Partners’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Sell
17,400
-7,600
-30% -$24.7K 0.01% 178
2026
Q1 		$74.5K Hold
25,000
– – 0.01% 173
2025
Q4 		$122K Buy
+25,000
New +$128K 0.02% 169

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

De Lisle Partners's NEPH Position: Q2 2026 in Review

De Lisle Partners reduced its Nephros (NEPH) stake by 30% in Q2 2026, selling an estimated $24.7K and leaving 17,400 shares worth $62.1K. The position accounts for 0.01% of the portfolio, ranked #178.

De Lisle Partners first reported a position in NEPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $122K in Q4 2025. 33 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • De Lisle Partners held 17,400 shares of Nephros worth $62.1K as of Q2 2026.
  • De Lisle Partners sold 7,600 Nephros shares in Q2 2026, an estimated $24.7K.
  • Nephros made up 0.01% of De Lisle Partners's portfolio in Q2 2026, its #178 holding.
  • De Lisle Partners first reported a position in Nephros in Q4 2025 and has held it in 3 quarters since.
  • De Lisle Partners's Nephros position peaked at $122K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on De Lisle Partners's 13F filing for Q2 2026, filed 12 Aug 2026.